This has quietly been a miracle month in medicine. In the last 5 weeks we’ve got news on: - retatrutide, the triple agonist GLP-1 from Lilly, basically melting fat and body-wide inflammation at record levels - RevMed’s new pancreatic cancer drug showing unprecedented

•

Crémieux

@cremieuxrecueil · Twitter · 2026-05-31 05:24 UTC

This is actually insane. 97% of people taking the standard of care for metastatic solid tumor got worse by seven years. But with lorlatinib, that number was only 45% in the same time! This is an ENORMOUS jump in the quality of cancer care.